Tema Etfs LLC Sells 18,081 Shares of Merus N.V. $MRUS

Tema Etfs LLC reduced its stake in Merus N.V. (NASDAQ:MRUS) by 35.3% during the third quarter, Holdings Channel.com reports. The fund owned 33,134 shares of the biotechnology company’s stock after selling 18,081 shares during the period. Tema Etfs LLC’s holdings in Merus were worth $3,120,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Merus by 14.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 112,522 shares of the biotechnology company’s stock valued at $4,736,000 after purchasing an additional 13,778 shares during the period. Voya Investment Management LLC boosted its stake in shares of Merus by 26.3% in the 1st quarter. Voya Investment Management LLC now owns 78,280 shares of the biotechnology company’s stock valued at $3,295,000 after purchasing an additional 16,280 shares during the last quarter. Harbour Capital Advisors LLC increased its position in shares of Merus by 69.2% during the second quarter. Harbour Capital Advisors LLC now owns 14,130 shares of the biotechnology company’s stock worth $754,000 after buying an additional 5,780 shares during the period. Atle Fund Management AB increased its position in shares of Merus by 69.7% during the second quarter. Atle Fund Management AB now owns 59,889 shares of the biotechnology company’s stock worth $3,150,000 after buying an additional 24,597 shares during the period. Finally, Avanza Fonder AB raised its stake in Merus by 14.1% during the second quarter. Avanza Fonder AB now owns 3,136 shares of the biotechnology company’s stock worth $165,000 after buying an additional 387 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Insider Activity at Merus

In other news, major shareholder A/S Genmab bought 1,052,806 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were bought at an average cost of $97.00 per share, for a total transaction of $102,122,182.00. Following the acquisition, the insider directly owned 73,884,293 shares in the company, valued at approximately $7,166,776,421. This trade represents a 1.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Harry Shuman sold 8,300 shares of Merus stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $95.92, for a total transaction of $796,136.00. Following the completion of the sale, the vice president directly owned 11,002 shares of the company’s stock, valued at approximately $1,055,311.84. The trade was a 43.00% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders acquired 2,421,216 shares of company stock worth $234,857,952. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analyst Weigh In

MRUS has been the topic of a number of research analyst reports. Citigroup cut shares of Merus from a “buy” rating to a “neutral” rating and cut their price target for the company from $101.00 to $97.00 in a research report on Monday, September 29th. William Blair downgraded Merus from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. HC Wainwright cut Merus from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $135.00 to $97.00 in a research note on Monday, September 29th. BMO Capital Markets reissued a “market perform” rating and issued a $97.00 price target on shares of Merus in a research note on Friday, October 31st. Finally, Leerink Partners restated a “market perform” rating and set a $97.00 price target (up from $95.00) on shares of Merus in a report on Monday, October 6th. Three equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $93.56.

Merus Price Performance

Shares of MRUS opened at $90.00 on Monday. Merus N.V. has a one year low of $33.19 and a one year high of $97.14. The company has a market cap of $6.83 billion, a PE ratio of -16.98 and a beta of 1.06. The stock has a 50-day moving average of $94.93 and a 200-day moving average of $80.07.

Merus Profile

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.